Improving Albuminuria Screening Compliance Using a Smartphone Urinalysis Kit
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03470701|
Recruitment Status : Not yet recruiting
First Posted : March 20, 2018
Last Update Posted : March 21, 2018
|Condition or disease||Intervention/treatment||Phase|
|Albuminuria Chronic Kidney Diseases Cardiovascular Diseases Hypertension||Other: Mailed Urinalysis Smartphone Kit||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1000 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Improving Albuminuria Screening Compliance Using a Smartphone Urinalysis Kit in the Hypertensive Non-Diabetic Population|
|Estimated Study Start Date :||April 2018|
|Estimated Primary Completion Date :||July 2018|
|Estimated Study Completion Date :||December 2018|
No Intervention: Control - usual care
This arm will receive usual care.
Experimental: Mailed Urinalysis Smartphone Kit
This arm will receive a mailed urinalysis smartphone kit if they do not complete albuminuria screening after the initial reminder to do so.
Other: Mailed Urinalysis Smartphone Kit
Patients who fail to complete albuminuria screening after the initial reminder to do so, will be contacted by phone and offered a mailed smartphone urinalysis kit. Agreeable patients will then receive the mailed kit and instructions to use their smartphone camera to analyze a urine dipstick.
- Completion of albuminuria screening [ Time Frame: Baseline to 3 months of enrollment date ]Includes completion of mailed smartphone urinalysis and clinical labs (urinalysis, albumin/creatinine ratio, or protein/creatinine ratio)
- Total number of detected albuminuria cases [ Time Frame: Baseline to 3 months of enrollment date ]confirmed by urine albumin/creatinine ratio >= 30 mg/g
- Achievement of optimal albuminuria treatment [ Time Frame: Baseline to 3 months of enrollment date ]Among patients with newly detected albuminuria, we will examine whether achievement of optimal albuminuria treatment (ACE or ARB, statin, BP goal <130/80 mmHg) improves at 3 months compared to baseline
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03470701
|Contact: Alex R Chang, MDemail@example.com|
|Contact: Christina Yule, BSfirstname.lastname@example.org|
|Principal Investigator:||Alex R Chang, MD||Geisinger Clinic|